Showing results (171-180 of 517) with videos related to

Sort By:
Pageof 52
Experimental Hematology|March 19, 2008
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cellsMichael P Kline, S Vincent Rajkumar, Michael M Timm, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 8, 2026
The International Myeloma Society Honors the Life and Legacy of Myeloma Pioneer Brian G. M. Durie, MD, PhD (1942-2025)Philippe Moreau, Shaji Kumar, Noopur S Raje, et al.
Mayo Clinic Proceedings|July 17, 2010
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experiencePrashant Kapoor, Patricia T Greipp, Eric W Schaefer, et al.
Plos One|May 11, 2023
RWD-derived response in multiple myelomaTao Xu, James Roose, Mellissa Williamson, et al.
British Journal of Haematology|January 11, 2005
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical applicationToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.
Bone Marrow Transplantation|March 17, 2022
Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplantDhauna Karam, Morie Gertz, Martha Lacy, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|February 15, 2017
Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 ConferenceUday Yanamandra, Navin Khattry, Shaji Kumar, et al.
British Journal of Haematology|October 9, 2003
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myelomaMichael A Thompson, Thomas E Witzig, Shaji Kumar, et al.
European Journal of Haematology|May 19, 2010
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myelomaFrancesca Gay, S Vincent Rajkumar, Patrizia Falco, et al.
Hematological Oncology|September 23, 2023
Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safetyMohamed Badawi, Sheryl Coppola, Doerthe Eckert, et al.
Pageof 52